Pharmaceutical Polymorphs and Cocrystals and Their In Vitro and In Vivo Evaluation
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: 20 July 2025 | Viewed by 12884
Special Issue Editors
2. Beijing Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Beijing 100050, China
Interests: new technologies and methods for pharmaceutical analysis; polymorphic drugs; quality control of drugs; druggability evaluation of innovative drug
2. Beijing Key Laboratory of Polymorphic Drugs, Center of Pharmaceutical Polymorphs, Beijing 100050, China
Interests: solid state pharmaceutical crystal chemistry; application of computational chemistry to pharmaceutical crystallography; evaluation of pharmaceutical cocrystal in vitro and in vivo
Special Issue Information
Dear Colleagues,
Approximately 90% of new chemical entities and 40% of marketed drugs belong to biopharmaceutical classification system (BCS) classes II or IV, which have poor water solubility and/or poor permeability. These defects result in low bioavailability. The formation of different polymorphs and co-crystals has been proven to be an important method to effectively improve the physicochemical properties, in vivo metabolic processes and bioavailability of these insoluble compounds. Through the efforts of many researchers, many new polymorphs or co-crystals of these compounds have been discovered. Some of them, such as Entresto (sacubitril valsartan sodium tablet, the first co-crystal drug approved by the FDA) and Seglentis (tramadol hydrochloride and celecoxib), after rigorous preclinical research and clinical trials, have been marketed for clinical service. The research on the polymorphs and co-crystals of these compounds provides new approaches and broad prospects for drug development.
The efficient design, screening and preparation of different polymorphs and co-crystals of drugs, and accurate and scientific evaluation of their physical and chemical properties and in vitro and in vivo processes are the key points in drug research and development. We encourage the submission of research studies exploring these topics to this Special Issue. The different solid states of chemicals affect their physicochemical properties (e.g., solubility, permeability and stability) and in vivo processes (e.g., absorption and distribution), thus affecting bioavailability. Through systematic studies, the optimal crystal forms or co-crystals of drugs can be screened to improve their medicinal properties. This Special Issue aims to explore new research ideas for enriching material resources and promoting drug research and development.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Drug permeability improvement and in vitro and in vivo evaluation;
- Solubility improvement of insoluble drugs and in vitro and in vivo evaluation;
- Study on the mechanisms of improvement of physical and chemical properties of different drug polymorphs or co-crystals;
- New methods for evaluating the solubility and permeability of different drug polymorphs or co-crystals;
- Studies on pharmacokinetics of different drug polymorphs or co-crystals in vivo.
We look forward to receiving your contributions.
Prof. Dr. Li Zhang
Prof. Dr. Dezhi Yang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pharmaceutical polymorphs
- pharmaceutical cocrystals
- pharmaceutical salts
- solubility
- dissolution
- permeability
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
